Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine

Maïté Verreault, Dita Strutt, Dana Masin, +6

BMC Cancer

Irinophore C: A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy against a Panel of Human Xenograft Tumors

Euan C. Ramsay, Malathi Anantha, Jason Zastre, +6

Clinical Cancer Research

Characterization of Long-Circulating Cationic Nanoparticle Formulations Consisting of a Two-Stage PEGylation Step for the Delivery of siRNA in a Breast Cancer Tumor Model

Emmanuel A. Ho, Maryam Osooly, Dita Strutt, +4

Journal of Pharmaceutical Sciences

NanoparticlesNanomedicineTwo-stage Pegylation StepEngineeringNano-drug Delivery +3

Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model

Maïté Verreault, Dita Strutt, Dana Masin, +4

Journal of Controlled Release

Neuro-oncologyNanomedicineLipid-based Nanoparticulate FormulationNanotherapeuticsDrug Targeting +12

Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer

Nilesh A. Patankar, Dawn Waterhouse, Dita Strutt, +2

Investigational New Drugs

NanomedicineEngineeringLiposomal Nanoparticle FormulationNano-drug DeliveryTumor Targeting +5

Combined RNAi-Mediated Suppression of Rictor and EGFR Resulted in Complete Tumor Regression in an Orthotopic Glioblastoma Tumor Model

Maïté Verreault, Sherry A. Weppler, Amelia Stegeman, +4

PLoS ONE

Complete Tumor RegressionCancer BiologyGliomaTumor BiologyOncology +16

Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer

Robert W. Neijzen, May Q. Wong, Navdeep Gill, +9

Journal of Controlled Release

Tumor BiologyNanomedicineDrug TargetingOncologyNanotherapeutics +12

Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma

Maïté Verreault, Mohamed Wehbe, Dita Strutt, +9

Journal of Controlled Release

Neuro-oncologyOncologyGliomaMedicineMetronomic Therapy +11

Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities

Dawn Waterhouse, Brent W. Sutherland, Nancy Dos Santos, +10

Investigational New Drugs